Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
Hemispherx Biopharma Will Be Presenting at The Wall Street Analyst Forum in New York on September 9, 2002
Hemispherx Biopharma Receives Letter of Intent for Potential Multimillion-dollar Investment by Royal Family of United Arab Emirates
HEMISPHERX ANNOUNCES SECOND QUARTER RESULTS
HEMISPHERX ANNOUNCES DETAILS ON WALL STREET REPORTER ROUNDTABLE SCHEDULED FOR WEDNESDAY JULY 31ST AT 2 PM EST
HEMISPHERX ANNOUNCES CONFERENCE CALENDAR
HEMISPHERX REPORTS NEW AMPLIGEN DATA DEMONSTRATING A MEDIAN 0.5 LOG DROP IN VIRAL LOAD AT INTERNATIONAL AIDS CONFERENCE IN BARCELONA
HEMISPHERX REPORTS AMPLIGEN DATA DEMONSTRATING A MEDIAN HAART-FREE (STI) INTERVAL OF 25+ WEEKS AT INTERNATIONAL AIDS CONFERENCE IN BARCELONA
HEMISPHERX SCHEDULES CONFERENCE CALL TO REVIEW NEW DATA PRESENTED AT THE INTERNATIONAL AIDS CONFERENCE IN BARCELONA.
Hemispherx Announces Annual Shareholders Meeting To Be Held August 14th, 2002
Abstracts cover latest developments in the Company's HIV/AIDS Clinical Trials for Salvage Therapy and Strategic Treatment Intervention (STI)
75
76
77
78
79
80
81
82
83
<<
<
>
>>
Privacy